Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
2024年7月3日 - 5:00PM
- Pneumagen has previously reported positive results from both
Phase 1 and a clinical proof of concept Phase 2 Human Influenza
Challenge study demonstrating the potential of Neumifil
- New preclinical data, published in peer-reviewed journal
Antiviral Research, show Neumifil demonstrates broad-spectrum
efficacy against a wide range of viruses including influenza virus,
respiratory syncytial virus, coronavirus and rhinovirus
- These studies confirm Neumifil’s ability to block virus
engagement of host receptors to inhibit infection with reduced risk
of antiviral resistance
- Findings support further clinical development of Neumifil in
vulnerable populations to provide broad-spectrum protection against
recurring seasonal infections or newly emerging viral threats
St Andrews, UK – 3 July 2024 - Pneumagen, a
clinical stage biotech company developing Neumifil (HEX17), a
broad-spectrum antiviral, intranasal drug for the prophylaxis and
treatment of viral respiratory tract infections (RTIs), announces
the publication of new preclinical data evaluating Neumifil in a
wide range of viral disease models. These preclinical data are
published in the peer-reviewed journal, Antiviral Research in a
paper entitled, “HEX17(Neumifil): An intranasal respiratory
biotherapeutic with broad-acting antiviral activity,” and confirm
the potential of Neumifil as a first in class protein-based
antiviral prophylactic for respiratory viral infections. The
article can be accessed online at
https://doi.org/10.1016/j.antiviral.2024.105945.
The publication highlights that Neumifil (HEX17) demonstrates
consistent broad-spectrum efficacy against a wide range of viral
respiratory pathogens including influenza virus, respiratory
syncytial virus, coronavirus and human rhinovirus in multiple in
vivo and in vitro studies. These viruses pose a severe threat to
human health, particularly in the very young or old, or in those
with pre-existing respiratory conditions such as asthma or chronic
obstructive pulmonary disease (COPD).
This new research, showing protection against multiple key
respiratory pathogens, taken together with a previously reported
positive Phase 2 human influenza challenge study, which
demonstrated an encouraging clinical safety and efficacy profile
(Phase 2 Results here) is strongly supportive of further clinical
development of Neumifil for the prevention of respiratory viral
infections in high-risk subjects, such as those with COPD.
Professor Garry Taylor, Chair of the Scientific Advisory
Board of Pneumagen said: “There is an urgent need for
broad-acting antiviral strategies to prevent respiratory tract
infections. Emerging or re-emerging viral diseases, including most
recently H5N1, caused by new or genetic variants of existing
viruses represent a severe threat to human health, particularly in
those with pre-existing respiratory conditions such as asthma or
chronic obstructive pulmonary disease (COPD). As confirmed by this
comprehensive early preclinical data set, Neumifil shows great
promise as a potential wide-ranging antiviral prophylactic that
could significantly reduce the risk and severity of infections in
these high-risk groups, ensuring better health outcomes and
providing an important new weapon against existing and emerging
viral threats.”
Douglas Thomson CEO of Pneumagen added:
“Publication of the impressive results from our wide-ranging
preclinical studies with Neumifil provides important confirmation
of its broad-spectrum activity. Based on our early data, we have
moved rapidly to progress Neumifil into clinical development and
our positive Phase 1 and Phase 2 CHIM studies further reinforce our
confidence in Neumifil as a potentially important treatment option
for at-risk patients. We now look forward to advancing Neumifil
into further clinical studies where its broad spectrum of activity
offers significant promise. These trials are expected to include
the evaluation of Neumifil’s ability to reduce the incidence of
exacerbations in COPD patients.”
END
About Pneumagen
Pneumagen is a clinical-stage biotech company developing
Neumifil, its lead product, a broad-spectrum antiviral, intranasal
drug for the prophylaxis and treatment of viral respiratory tract
infections (RTIs).
Neumifil is a novel, engineered, multivalent, Carbohydrate
Binding Module (mCBM). It acts by directly binding and preventing
the entry into the host of the viral pathogens. Neumifil was
generated using Pneumagen’s proprietary GlycoTarge™ technology.
Pneumagen was established in 2016 as a spin-out from the
University of St Andrews in Scotland giving Pneumagen access to
world-class scientific expertise and capabilities in viral
infections specifically related to glycobiology.
For further information, please contact:
Pneumagen
Douglas Thomson, CEO
Email:
info@pneumagen.com
MEDiSTRAVA Consulting (Financial
PR)
Frazer Hall, Sandi Greenwood
Email: Pneumagen@medistrava.com